Guangzhou Kingmed Diagnostics Group Past Earnings Performance
Past criteria checks 1/6
Guangzhou Kingmed Diagnostics Group has been growing earnings at an average annual rate of 0.1%, while the Healthcare industry saw earnings growing at 2% annually. Revenues have been growing at an average rate of 8.7% per year. Guangzhou Kingmed Diagnostics Group's return on equity is 1.9%, and it has net margins of 2.1%.
Key information
0.1%
Earnings growth rate
-0.2%
EPS growth rate
Healthcare Industry Growth | 7.0% |
Revenue growth rate | 8.7% |
Return on equity | 1.9% |
Net Margin | 2.1% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Guangzhou Kingmed Diagnostics Group's (SHSE:603882) Weak Earnings May Only Reveal A Part Of The Whole Picture
Nov 06Guangzhou Kingmed Diagnostics Group's (SHSE:603882) Shareholders Have More To Worry About Than Only Soft Earnings
May 02Recent updates
Guangzhou Kingmed Diagnostics Group's (SHSE:603882) Weak Earnings May Only Reveal A Part Of The Whole Picture
Nov 06Earnings Tell The Story For Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882)
Sep 27Guangzhou Kingmed Diagnostics Group Co., Ltd. Just Missed Revenue By 9.5%: Here's What Analysts Think Will Happen Next
Sep 03Is Guangzhou Kingmed Diagnostics Group (SHSE:603882) Using Too Much Debt?
Aug 25A Look At The Fair Value Of Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882)
Jun 04Guangzhou Kingmed Diagnostics Group's (SHSE:603882) Shareholders Have More To Worry About Than Only Soft Earnings
May 02Investors Don't See Light At End Of Guangzhou Kingmed Diagnostics Group Co., Ltd.'s (SHSE:603882) Tunnel And Push Stock Down 26%
Apr 17Investor Optimism Abounds Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882) But Growth Is Lacking
Feb 28Revenue & Expenses Breakdown
How Guangzhou Kingmed Diagnostics Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 7,849 | 161 | 2,154 | 404 |
30 Jun 24 | 8,251 | 448 | 2,188 | 410 |
31 Mar 24 | 8,263 | 475 | 2,231 | 428 |
31 Dec 23 | 8,540 | 643 | 2,218 | 467 |
30 Sep 23 | 9,578 | 882 | 2,349 | 541 |
30 Jun 23 | 11,052 | 1,397 | 2,465 | 583 |
31 Mar 23 | 13,342 | 2,054 | 2,525 | 622 |
31 Dec 22 | 15,476 | 2,755 | 2,761 | 633 |
30 Sep 22 | 15,534 | 2,996 | 2,807 | 613 |
30 Jun 22 | 14,800 | 2,803 | 2,734 | 597 |
31 Mar 22 | 13,516 | 2,532 | 2,648 | 554 |
31 Dec 21 | 11,943 | 2,220 | 2,394 | 518 |
30 Sep 21 | 11,034 | 2,127 | 2,188 | 471 |
30 Jun 21 | 10,225 | 2,013 | 2,014 | 443 |
31 Mar 21 | 9,752 | 2,000 | 1,869 | 434 |
31 Dec 20 | 8,244 | 1,510 | 1,660 | 397 |
30 Sep 20 | 7,176 | 1,138 | 1,461 | 381 |
30 Jun 20 | 6,201 | 787 | 1,372 | 359 |
31 Mar 20 | 5,276 | 408 | 1,289 | 333 |
31 Dec 19 | 5,269 | 402 | 1,312 | 324 |
30 Sep 19 | 5,128 | 388 | 1,275 | 303 |
30 Jun 19 | 4,954 | 309 | 1,242 | 293 |
31 Mar 19 | 4,771 | 266 | 1,214 | 281 |
31 Dec 18 | 4,525 | 233 | 1,156 | 291 |
30 Sep 18 | 4,309 | 205 | 1,142 | 284 |
30 Jun 18 | 4,107 | 200 | 974 | 398 |
31 Mar 18 | 3,909 | 191 | 1,007 | 326 |
31 Dec 17 | 3,792 | 189 | 1,043 | 256 |
30 Sep 17 | 3,689 | 198 | 1,066 | 191 |
31 Dec 16 | 3,222 | 170 | 1,141 | 0 |
30 Sep 16 | 3,010 | 153 | 1,087 | 0 |
31 Dec 15 | 2,389 | 140 | 891 | 0 |
31 Dec 14 | 1,838 | 71 | 731 | 0 |
31 Dec 13 | 1,356 | 52 | 507 | 0 |
Quality Earnings: 603882 has a large one-off gain of CN¥75.0M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 603882's current net profit margins (2.1%) are lower than last year (9.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603882's earnings have grown by 0.1% per year over the past 5 years.
Accelerating Growth: 603882's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 603882 had negative earnings growth (-81.7%) over the past year, making it difficult to compare to the Healthcare industry average (-5.7%).
Return on Equity
High ROE: 603882's Return on Equity (1.9%) is considered low.